Biotronik launches BioMonitor implantable cardiac device in Europe


Biotronik has announced the European launch of BioMonitor. The device is a subcutaneous implantable leadless cardiac monitor for the long-term continuous remote monitoring of patients with arrhythmias such as atrial fibrillation (AF), bradycardia, sudden rate drop, asystole and tachycardia.

BioMontor features ClearSense technology, a unique three-vector signal detection technology that produces highly precise and reliable arrhythmia monitoring.

The ClearSense Technology records three ECG channels converting them to one high quality ECG input signal to clearly distinguish on a beat-to-beat basis between a genuine signal and other artifacts such as myopotentials due to body muscle contractions. This innovative technology allows for optimal arrhythmia detection independent of the device’s implant orientation within the body and provides a longevity of 6.4 years.

BioMonitor is also equipped with Biotronik’s home monitoring system, which provides daily remote data transfer without patient interaction-leading to high patient compliance. Its traffic light system streamlines monitoring by highlighting the most relevant information and providing accurate data for physicians to monitor and manage their patients effectively.

“Only long-term continuous monitoring with reliable arrhythmia detection offers the type of vital information necessary for physicians to make the right therapy decisions when managing patients with AF or unexplained syncope,” said Gerhard Hindricks, director of the Department of Electrophysiology at the Leipzig University Heart Center in Germany.

Hindricks together with Wilhelm Haverkamp (deputy of the Department of Cardiology at Charité Campus Virchow, Humboldt University, Berlin, Germany), and Dietmar Bänsch (director of Cardiology Department and Rhythmology at the Rostock University Hospital, Germany) are the world’s first physicians to implant the BioMonitor.

“Effective management of AF and unexplained syncope starts with effective monitoring,” said Haverkamp. “BioMonitor, with its ClearSense technology, and Biotronik Home Monitoring offer the optimal combination of reliability and efficiency.”

“BioMonitor supports physicians in every step of arrhythmia management, from diagnosis via monitoring to individualised therapy offering high quality solutions that benefit both physicians and patients,” commented Bänsch.